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IMPORTANCE Digital ulcers in patients with systemic sclerosis are associated with pain and
poor quality of life. Endothelin-1 promotes vasculopathy in systemic sclerosis after
macitentan, an endothelin-1 blocker.
OBJECTIVE To evaluate the efficacy of macitentan in reducing the number of new digital
ulcers in patients with systemic sclerosis.
DESIGN, SETTING, AND PARTICIPANTS Two international, randomized, double-blind,
placebo-controlled trials (DUAL-1, DUAL-2) were conducted between January 2012 and
February 2014. Participants were patients with systemic sclerosis and active digital ulcers at
baseline. Target enrollment for each study was 285 patients.
INTERVENTIONS Patients were randomized (1:1:1) to receive oral doses of 3 mg of macitentan,
10 mg of macitentan, or placebo once daily and stratified according to number of digital
ulcers at baseline (3 or >3).
MAIN OUTCOMES AND MEASURES The primary outcome for each trial was the cumulative
number of new digital ulcers from baseline to week 16. Treatment effect was expressed as the
ratio between treatment groups.
RESULTS In DUAL-1, among 289 randomized patients (mean age 51.2 years; 85.8% women),
226 completed the study. The adjusted mean number of new digital ulcers per patient over 16
weeks was 0.94 in the 3-mg macitentan group (n = 95) and 1.08 in the 10-mg macitentan
group (n = 97) compared with 0.85 in the placebo group (n = 97) (absolute difference, 0.09
[95% CI, −0.37 to 0.54] for 3 mg of macitentan vs placebo and 0.23 [−0.27 to 0.72] for 10 mg
of macitentan vs placebo). Among 265 patients randomized in DUAL-2 (mean age 49.6 years;
81.9% women), 216 completed the study. In DUAL-2, the adjusted mean number of new
digital ulcers was 1.44 in the 3-mg macitentan group (n = 88) and 1.46 in the 10-mg
macitentan group (n = 88) compared with 1.21 in the placebo group (n = 89) (absolute
difference, 0.23 [95% CI, −0.35 to 0.82] for 3 mg of macitentan vs placebo and 0.25 [95% CI,
−0.34 to 0.84] for 10 mg of macitentan vs placebo). Adverse events more frequently
associated with macitentan than with placebo were headache, peripheral edema, skin ulcer,
anemia, upper respiratory tract infection, diarrhea, and nasopharyngitis.
CONCLUSIONS AND RELEVANCE Among patients with systemic sclerosis and active ischemic
digital ulcers, treatment with macitentan did not reduce new digital ulcers over 16 weeks.
These results do not support the use of macitentan for the treatment of digital ulcers in this
patient population.
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S ystemic sclerosis is a chronic multisystem autoim-mune disease characterized by systemic vascular dys-function and fibroblast dysregulation.1 Microvascular in-
volvement contributes to the pathogenesis of the hallmark
manifestations in systemic sclerosis, including pulmonary ar-
terial hypertension, scleroderma renal crisis, Raynaud phe-
nomenon, and digital ischemia.1 Digital ulcers are a clinical
manifestation of digital ischemia that occur in 35% to 68% of
patients with systemic sclerosis2-5 and are associated with pain,
disfigurement, poor quality of life, and disability.2,6
Systemic sclerosis–related vasculopathy is associated with
the initiation and progression of systemic sclerosis and the de-
velopment of digital ulcers.7 Endothelin-1 (ET-1) is a mediator of
vascular hypertrophy, proliferation, inflammation, and fibrosis.8
ET-1 is overexpressed in plasma in patients with systemic scle-
rosis, especially those with digital ulcers.9 ET receptors are up-
regulated in microvessels of skin in systemic sclerosis.10 The
dualET-receptorantagonist(ERA)bosentansignificantlyreduced
the number of new digital ulcers in 2 randomized clinical trials
(RCTs) of patients with systemic sclerosis with digital ulcers.11,12
Macitentan is a novel dual ERA13,14 approved for long-term treat-
ment of pulmonary arterial hypertension.
DUAL-1 and DUAL-2 are 2 RCTs that evaluated whether
macitentan reduces the number of new digital ulcers and their
associated disability in patients with systemic sclerosis and ac-
tive ischemic digital ulcers. DUAL-1 and DUAL-2 also evalu-




DUAL-1 and DUAL-2 were phase 3, randomized, double-blind,
placebo-controlled, multicenter, parallel-group trials, de-
signed to fulfill the regulatory requirement for providing sub-
stantial evidence of effectiveness. Patients were enrolled in
DUAL-1 at 70 centers in 17 countries from January 2012 to
November 2013 and in DUAL-2 at 73 centers in 20 countries from
February 2012 to February 2014. Investigational sites were spe-
cific to each study; although, 6 countries were involved in both
trials (eFigure in Supplement 1). The trial protocols (Supplement
2 and Supplement 3) were approved by ethics committees at
each center and the studies were performed in accordance with
the principles of the Declaration of Helsinki and within the regu-
lations of each country. Written informed consent was ob-
tained from all patients. An independent data monitoring com-
mittee regularly reviewed unblinded efficacy and safety data,
and an international liver safety board assessed all hepatic events
(eTable 1 in Supplement 1).
Participant Selection
Inclusion criteria were age of at least 18 years; physician diag-
nosis of systemic sclerosis according to the 1980 American
College of Rheumatology classification criteria15 with limited or
diffuse cutaneous systemic sclerosis16; at least 1 visible, active
ischemic digital ulcer located at or distal to the proximal inter-
phalangeal jointthatdevelopedorworsenedwithin8weeksprior
to screening; and a history of additional active digital ulcers
prior to screening (≥1 within 6 months or ≥2 within 12 months).
An active digital ulcer was defined as a finger lesion with visu-
ally discernible depth and a loss of continuity of epithelial cov-
erage associated with pain not attributable to other etiologies.
Patients were excluded if they had digital ulcers not due
to systemic sclerosis, or if they had comorbidities that could
affect assessment of hand function. Other exclusion criteria
included any severe organ failure or life-threatening condi-
tion; tobacco use within 6 months before screening; treat-
ment with phosphodiesterase type 5 inhibitors; treatment with
prostanoids or ERAs within 3 months prior to screening or any
investigational drug within 1 month prior to screening; and dis-
ease-modifying agents given for less than 3 months or at a non-
stable dose for at least 1 month prior to screening.
Study Procedures
In each study, patients were randomly assigned (1:1:1) to re-
ceive 3 mg of macitentan, 10 mg of macitentan, or matching
oral placebo once daily. Treatment allocation was stratified by
number of digital ulcers at randomization (≤3 and >3) with a
block size of 6. Each patient was randomized via a central-
ized Interactive Response System (ICON) and received a unique
randomization number. The patients, investigators, and study
sponsor remained blinded to treatment until database lock.
Patients were assessed at randomization and every 4 weeks
up to week 16 (period 1). Between week 16 and the end of the
study they were assessed every 3 months (period 2) (eTable 2 in
Supplement 1). Patients continued double-blind treatment un-
til the end of study, which occurred for all patients when the last
patient completed the week-16 visit. Within 7 days of the end of
the study, patients completed the end of treatment visit. Within
30 days of the end of the study, patients underwent their end-
of-study visit. Patients who prematurely discontinued the study
drug in period 1 or 2 completed the end of treatment visit within
7 days of the last administered dose. These patients underwent
follow-up every 3 months until the end of the study. Adverse
events (AEs) were monitored throughout the study.
Outcome Measures
The primary efficacy end point was the cumulative number
of new digital ulcers from baseline to week 16. Digital ulcers
that occurred and healed between visits were not recorded as
new. Complete healing was defined as complete epitheliali-
zation of the ischemic digital ulcer, regardless of residual pain.
Since there is low interrater reliability in assessing digital
ulcers,17 each patient was assessed for digital ulcers by the same
investigator throughout the study. All investigators were
trained to visualize and score the stages and types of digital
ulcers in face-to-face meetings and were provided with a ref-
erence document to use during the study.
Other prespecified end points included the evaluation of
hand function (assessed by the change between baseline and
week 16 in Health Assessment Questionnaire-Disability In-
dex [HAQ-DI]18 and Hand Disability in Systemic Sclerosis-
Digital Ulcers [HDISS-DU] scores [eMethod in Supplement 1]);
the evaluation of digital ulcer burden (assessed by the propor-
tion of patients with or without multiple new digital ulcers at
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week 16 and by the change from baseline to week 16 in the total
number of digital ulcers); the change from baseline to week 16
in the patient- and physician-reported global assessment of
digital ulcer activity (severity of illness and global improve-
ment; score range, 1-7); the proportion of patients with com-
plete healing of all digital ulcers at week 16; the change from
baseline to week 16 in overall hand pain related to digital ul-
cers (score range, 1-10); the change from baseline to week 16
in the Scleroderma Health Assessment Questionnaire visual
analog scales (SHAQ-VAS; score range, 1-3) for overall global
assessment of disease and for activity limitation due to digi-
tal ulcers and to Raynaud phenomenon19; and the evaluation
of digital ulcer complications (assessed by the proportion of
patients with digital ulcer complications at the end of treat-
ment and the time from randomization to first digital ulcer
complication up to the end of treatment).
Statistical Analyses
For the primary end point, the null hypotheses were that the
mean cumulative number of new digital ulcers per patient up
to week 16 was the same between placebo vs 10-mg maciten-
tan groups and between placebo vs 3-mg macitentan groups.
A sample size of 95 patients per treatment group (285 pa-
tients in total) was calculated by statistical simulations on the
basis of a 2-sided comparison at the 5% significance level using
an unstratified Pitman permutation test, 90% power, an over-
dispersion of 0.76, and an estimated 45% reduction in new digi-
tal ulcers at week 16 (based on an RCT comparing bosentan vs
placebo, in which the mean number of new digital ulcers up
to week 24 was 4.4 for placebo and 2.4 for bosentan).12 The
use of a binomial-2 regression (NB-2) model20 adjusted for the
number of digital ulcers at randomization (≤3 or >3) was in-
troduced before study start. With the same sample size, it was
estimated that a significant difference between the active and
the placebo groups could be determined with greater than 97%
power. The treatment effect was expressed as the ratio of in-
cidence rates of new digital ulcers over 16 weeks between each
of the macitentan dose groups and the placebo group, and pre-
sented with corresponding 95% CIs. The incidence rates were
calculated as the cumulative number of new digital ulcers ob-
served up to week 16 and were standardized to 16 weeks to ac-
count for different exposure times among patients. The main
imputation rules for missing values for the primary end point
are explained in eTable 3 in Supplement 1. This imputation
method relies on the assumption of a constant rate of new digi-
tal ulcers occurring over time, as observed in previous
studies11,12 and verified post hoc for these analyses.
A post hoc sensitivity analysis was performed using mul-
tiple imputation by fully conditional specification.21 Vari-
ables used for imputation were treatment group, number of
digital ulcers at randomization, and the count of new digital
ulcers at each visit up to week 16 (eTable 4 in Supplement 1).
Additional predefined sensitivity analyses of the primary end
point were performed, as detailed in eTable 4 (Supplement 1).
A prespecified subgroup analysis evaluated the primary end
point by number of digital ulcers at randomization (≤3 or >3).
For other efficacy end points evaluating a change from base-
line to week 16, treatment differences were analyzed using analy-
sis of covariance. Treatment differences for binary efficacy end
points were expressed as odds ratios (ORs) calculated using lo-
gistic regression. Treatment differences were adjusted for base-
line values. Missing data at week 16 were imputed using the last
observation carried forward, and for HAQ-DI, the standard scor-
ing was used.19 For time-to-event analyses, Kaplan-Meier esti-
mates were calculated and proportional hazard models were
used to compute hazard ratios (HRs) and 95% CIs. All analyses
were adjusted for the number of digital ulcers at randomiza-
tion (≤3 or >3). Safety data were summarized descriptively.
The primary end point analysis was performed in the
intention-to-treat population, whereas all other efficacy end
point analyses were performed in the modified intention-to-
treat population (defined as all randomized patients who re-
ceived ≥1 dose of study treatment and had ≥1 post-baseline pri-
mary efficacy assessment). The safety analysis included all
randomized patients who received at least 1 dose of study treat-
ment. The studies were planned to be reported separately. All
analyses were conducted using SAS version 9.3 (SAS Institute
Inc), using a significance threshold of 5% with 2-sided P values.
Results
Patient Characteristics
In the DUAL-1 study, 289 patients were randomized to receive
3 mg of macitentan (n = 95), 10 mg of macitentan (n = 97), or
placebo (n = 97) (Figure 1). In the DUAL-2 study, 265 patients
were randomized to receive 3 mg of macitentan (n = 88), 10 mg
of macitentan (n = 88), or placebo (n = 89) (Figure 2). In each
study, groups were balanced with respect to patient demo-
graphics, disease characteristics, and concomitant medica-
tions (Table 1). In DUAL-1, the number of digital ulcers at base-
line ranged from 1 to 13 (mean, 3.4), and 201 patients (69.6%)
presented with 3 or fewer digital ulcers. In DUAL-2, the num-
ber of digital ulcers at baseline ranged from 1 to 18 (mean, 3.5),
and 180 patients (67.9%) presented with 3 or fewer digital ul-
cers. DUAL-2 was terminated prematurely based on recommen-
dations by the independent data monitoring committee, which
had overall responsibility for safeguarding the interests of the
study participants by monitoring safety and efficacy data. Al-
though formal interim analyses were not predefined, the com-
mittee concluded, after reviewing unblinded data during a rou-
tine safety monitoring meeting (November 2013), that while risks
of macitentan appeared modest, the possibility of any benefit
was small and additional data were not expected to result in a
positive primary outcome. The committee recommended that
DUAL-2 be halted and study treatment was discontinued in all
patients (93.0% of planned patients had been enrolled and 74.7%
of those underwent ≥16 weeks of treatment).
Development of New Digital Ulcers
The 2 trials did not achieve the primary end point of a reduc-
tion of cumulative number of new digital ulcers over 16 weeks
(Table 2). In DUAL-1, the adjusted mean numbers of new digital
ulcers per patient over 16 weeks were 0.94 in the 3 mg of maci-
tentan group, 1.08 in the 10 mg of macitentan group, and 0.85
in the placebo group, and observations were similar in DUAL-2
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(adjusted mean number of new digital ulcers per patient over 16
weeks: 1.44 in the 3 mg of macitentan group, 1.46 in the 10 mg
of macitentan group, and 1.21 in the placebo group). In DUAL-1,
the absolute difference for the cumulative number of new digi-
tal ulcers from baseline to week 16 was 0.09 (95% CI, −0.37 to
0.54) and the rate ratio was 1.10 (95% CI, 0.66 to 1.83) (P = .71)
for 3 mg of macitentan vs placebo; for 10 mg of macitentan vs
placebo, the absolute difference was 0.23 (95% CI, −0.27 to 0.72)
and the rate ratio was 1.27 (95% CI, 0.76 to 2.11) (P = .36).
In DUAL-2, the absolute difference for the cumulative num-
ber of new digital ulcers from baseline to week 16 was 0.23 (95%
CI, −0.35 to 0.82) and the rate ratio was 1.19 (95% CI, 0.77 to
1.86) (P = .43) for 3 mg of macitentan vs placebo; for 10 mg of
macitentan vs placebo, the absolute difference was 0.25 (95%
CI, −0.34 to 0.84) and the rate ratio was 1.21 (95% CI, 0.77 to
1.89) (P = .41). These results were confirmed using multiple im-
putation and other prespecified sensitivity analyses (eTable 4
in Supplement 1). The amount of missing data for the primary
end point is shown in eTable 5 (Supplement 1; patients with
≥1 missing assessment: DUAL-1, 23.5% [n = 68]; DUAL-2, 24.9%
[n = 66]). The absence of a treatment effect was also ob-
served in the subgroups of patients with 3 or fewer digital ul-
cers at baseline vs greater than 3 (Table 2). In DUAL-1, 64.1%
(59) of patients in the 3 mg of macitentan group, 63.0% (58)
of patients in the 10 mg of macitentan group, and 67.0% (63)
of patients in the placebo group had no new digital ulcers by
week 16. In DUAL-2, 56.0% (47) of those in the 3 mg of maci-
tentan group, 54.8% (46) of patients in the 10 mg of maciten-
tan group, and 59.8% (52) of patients in the placebo group had
no new digital ulcers by week 16 (Table 3).
Hand Function, Digital Ulcers Burden, and Time
to Digital Ulcers Complications
There were no treatment effects with either dose of maciten-
tan vs placebo in either trial with respect to other efficacy end
points, including hand function, digital ulcer burden, pa-
tient- and physician-reported outcomes, complete healing of
digital ulcers, and overall hand pain related to digital ulcers and
Figure 1. Flow of Study Participants for DUAL-1
327 Patients assessed for eligibility
38 Excluded
28 Did not meet inclusion criteria a





12 AST or ALT >1.5 ULN
5 BMI <18 b
289 Randomized
95 Included in ITT analysis
94 Included in safety analysis
92 Included in modified ITT analysis
3 Excluded (without postbaseline
digital ulcer assessments)
1 Excluded (did not receive
study drug)
97 Included in ITT and safety analyses
92 Included in modified ITT analysis
5 Excluded (without postbaseline
digital ulcer assessments)
97 Included in ITT and safety analyses
94 Included in modified ITT analysis
3 Excluded (without postbaseline
digital ulcer assessments)
95 Randomized to receive
macitentan, 3 mg
78 Treatment exposure
maintained at week 16 c
94 Received treatment as
randomized
1 Did not receive treatment as
randomized (administrative
reasons)
97 Randomized to receive
macitentan, 10 mg
97 Received treatment as
randomized
75 Treatment exposure
maintained at week 16 c
97 Randomized to receive placebo
97 Received placebo as
randomized
82 Treatment exposure





















2 Lost to follow-up
1 Physician decision
70 Completed study regardless of
treatment discontinuation
73 Completed study regardless of
treatment discontinuation
83 Completed study regardless of
treatment discontinuation
a Because multiple exclusions
may apply to individual patients,
subcategories will not sum
to the total.
b Calculated as weight in kilograms
divided by height in meters
squared.
c Because treatment could extend
beyond week 16, and because
premature discontinuation of
treatment could occur after week
16, values will not sum to the
number randomized for each group.
End of study, for all patients, was
defined as the time when the last
patient completed the week-16 visit.
Within 7 days afterwards, patients
completed the end of treatment visit,
and within 30 days, they underwent
the end-of-study visit. Patients who
prematurely discontinued study drug
in period 1 (randomization to week
16) or period 2 (after week 16 to end
of study) completed the
end-of-treatment visit within 7 days
of the last administered dose; these
patients (upon consent) continued to
undergo follow-up every 3 months
until the end of study. Adverse events
were monitored throughout the
study. The term completed study
refers to continued participation until
the end of study. AST indicates
aspartate aminotransferase;
ALT, alanine aminotransferase;
ULN, upper limit of normal;
BMI, body mass index;
ITT, intention-to-treat.
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SHAQ (Table 3). In all groups, patients showed reduction from
baseline to week 16 in total number of digital ulcers, severity
of disease (patient- and physician-rated), pain, and interfer-
ence with daily activity. There was little change in hand func-
tion (Table 3). In both trials, no differences between groups
were observed in time to first digital ulcer complications
(Figure 3). Digital ulcer complications were observed in 17.6%
of patients in DUAL-1 and in 21.2% of patients in DUAL-2 (eTable
6 in Supplement 1).
Safety and Tolerability
In both trials, patients were exposed to treatment on average for
40 weeks (eTable 7 in Supplement 1). In this period, the fre-
quency of patients in DUAL-1 with at least 1 AE was 71.3% among
those in the 3 mg of macitentan group, 76.3% for 10 mg of
macitentan , and 73.2% for the placebo group, and in DUAL-2,
the frequency of patients with at least 1 AE was 83.0% among
those in the 3 mg of macitentan group, 85.1% for 10 mg of maci-
tentan, and 78.7% for the placebo group (eTable 7 in Supplement
1). The most frequently reported AEs (incidence rate, 10% and
>3% difference between placebo and either macitentan group)
in each trial were headache, peripheral edema, skin ulcer, ane-
mia, upper respiratory tract infection, diarrhea, and nasophar-
yngitis. AEs leading to premature discontinuation occurred in
13.8% of patients in the 3 mg of macitentan group, 14.4% for 10
mg of macitentan, and 10.3% of patients in the placebo group
in DUAL-1, and in DUAL-2, AEs leading to premature discontinu-
ation occurred in 9.2% of patients in the 3 mg of macitentan
group, 17.2% for 10 mg of macitentan, and 14.6% of patients in
the placebo group. Skin ulcer, infected skin ulcer, and in-
creased alanine aminotransferase/aspartate aminotransferase
were the most frequently reported AEs leading to treatment dis-
continuation. Incidences of serious AEs in DUAL-1 were 18.1%
in the 3 mg of macitentan group, 14.4% for 10 mg of macitentan,
Figure 2. Flow of Study Participants for DUAL-2
59 Excluded a
55 Did not meet inclusion criteria a
8 Any condition preventing
protocol adherence
7 Digital ulcer did not meet
inclusion criterion





10 BMI <18 b
8 AST or ALT >1.5 ULN
265 Randomized
89 Included in ITT analysis
89 Included in safety analysis
87 Included in modified ITT analysis
2 Excluded (without postbaseline
digital ulcer assessments)
88 Included in ITT and safety analyses
84 Included in modified ITT analysis

















70 Completed study regardless of
treatment discontinuation
73 Completed study regardless of
treatment discontinuation
88 Randomized to receive
macitentan, 3 mg
65 Treatment exposure
maintained at week 16 c
88 Received treatment as
randomized
89 Randomized to receive placebo
89 Received placebo as
randomized
68 Treatment exposure
maintained at week 16 c
324 Patients assessed for eligibility
88 Included in ITT analysis
87 Included in safety analysis
84 Included in modified ITT analysis
4 Excluded (without postbaseline
digital ulcer assessments)









73 Completed study regardless of
treatment discontinuation
88 Randomized to receive
macitentan, 10 mg
65 Treatment exposure
maintained at week 16 c
87 Received treatment as
randomized
1 Did not receive treatment as
randomized (withdrew consent)
a Because multiple exclusions
may apply to individual patients,
subcategories will not sum
to the total.
b Calculated as weight in kilograms
divided by height in meters
squared.
c Because treatment could extend
beyond week 16, and because
premature discontinuation of
treatment could occur after week
16, values will not sum to the
number randomized for each group.
d Indicates the independent data
monitoring committee’s early
termination of the trial.
End of study, for all patients, was
defined as the time when the last
patient completed the week-16 visit.
Within 7 days afterwards, patients
completed the end of treatment visit,
and within 30 days, they underwent
the end-of-study visit. Patients who
prematurely discontinued study drug
in period 1 (randomization to week
16) or period 2 (after week 16 to end
of study) completed the
end-of-treatment visit within 7 days
of the last administered dose; these
patients (upon consent) continued to
undergo follow-up every 3 months
until the end of study. Adverse events
were monitored throughout the
study. The term completed study
refers to continued participation until
the end of study. BMI indicates body
mass index; AST, aspartate
aminotransferase; ALT, alanine
aminotransferase; ULN, upper limit of
normal; ITT, intention-to-treat.
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and 13.4% in the placebo group, and in DUAL-2, 11.4% in the 3 mg
of macitentan group, 24.1% for 10 mg of macitentan, and 14.6%
in the placebo group, with infections being the most common.
There was 1 death due to cardiac arrest in DUAL-1 in a patient
receiving 10 mg of macitentan. There were 2 deaths (1 due to un-
specified natural causes and 1 due to cardiac failure) in DUAL-2.
Both patients were in the 10 mg of macitentan group. All deaths
were considered unrelated to study treatment. There were no
differences in alanine aminotransferase, aspartate aminotrans-
ferase, bilirubin, or hemoglobin between study groups (eTable
7 in Supplement 1).
Discussion
In 2 randomized, placebo-controlled trials of patients with
systemic sclerosis and active ischemic digital ulcers at base-
line, macitentan did not reduce the cumulative number of
new digital ulcers over 16 weeks compared with placebo. Re-
gardless of treatment, patients had few new digital ulcers, and
their overall digital ulcer condition remained stable over
16 weeks. Macitentan was well tolerated, with a safety profile
similar to that observed in patients with pulmonary arterial
hypertension22 and idiopathic pulmonary fibrosis.23
Few therapies are available for digital ulcers in patients with
systemic sclerosis. The EUSTAR 2009 treatment recommen-
dations in systemic sclerosis for managing digital ulcers en-
dorse using intravenous iloprost and bosentan,24 and evi-
dence supporting the use of PDE-5 inhibitors is recently
available.25 Bosentan is the only treatment indicated to re-
duce the number of new digital ulcers in patients with sys-
temic sclerosis and ongoing digital ulcer disease, following 2
randomized clinical trials, RAPIDS-1 and RAPIDS-2.11,12 Be-
cause bosentan is not approved in all of the countries where
the DUAL studies were conducted, DUAL-1 and DUAL-2 did not
compare macitentan to bosentan. Instead, the trials were pla-
cebo-controlled with safeguards in place in case of progres-
sion of digital ulcer severity. The choice of bosentan as an active





























































































































































Digital ulcer complications were
defined as any of the following
(resulting from digital ulcer
worsening): (1) critical ischemic crisis
necessitating hospitalization;
(2) gangrene, (auto) amputation;
(3) failure of conservative
management: surgical and chemical
sympathectomy, vascular
reconstructions, or any unplanned
surgery in the management of hand
systemic sclerosis manifestations;
(4) use of parenteral prostanoids;
(5) use of endothelin receptor
antagonists; (6) required class 2, 3, or
4 narcotics or a >50%-increase in the
existing dose compared with
baseline; (7) initiation of systemic
antibiotics for the treatment of
infection attributed to digital ulcers.
A, Treatment effect for macitentan,
3 mg vs placebo: hazard ratio (HR),
0.77 (95% CI, 0.38-1.57); log-rank
P = .47; for macitentan, 10 mg vs
placebo: HR, 1.12 (95% CI, 0.58-2.15);
log-rank P = .74. The median duration
(Q1, Q3) of treatment exposure was
41.4 weeks (22.1, 59.9) in the
macitentan, 3-mg group, 37.4 weeks
(18.3, 63.5) in the macitentan, 10-mg
group, and 43.1 weeks (22.9, 65.1) in
the placebo group.
B, Treatment effect of macitentan,
3 mg vs placebo: HR, 1.19 (95% CI,
0.61-2.33); log-rank P = .62; for
macitentan, 10 mg vs placebo:
HR, 1.08 (95% CI, 0.4-2.15); log-rank
P = .84. The median duration (Q1, Q3)
of treatment exposure was 40.5
weeks (17.7, 61.7) in the macitentan,
3-mg group, 38.6 weeks (15.0, 62.1)
in the macitentan, 10-mg group,
and 37.4 weeks (17.0, 58.1) in the
placebo group.
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comparator would have limited the scope of the studies. Cur-
rent European guidelines state that bosentan should be con-
sidered in diffuse systemic sclerosis with multiple digital ul-
cers after failure of calcium antagonists and prostanoids.24
DUAL-1 and DUAL-2 were designed to fulfill the regulatory re-
quirements for demonstrating the effectiveness of maciten-
tan vs placebo.
Based on results of the RAPIDS trials, the inclusion crite-
ria of DUAL-1 and DUAL-2 were designed to enroll patients with
high likelihood of developing new digital ulcers. The number
of active digital ulcers at baseline ranged from 1 to 18 in the 2
studies. Although most participants (69.6%) had 3 or fewer digi-
tal ulcers at baseline, the average number of digital ulcers was
3.5, thus the study population consisted of systemic sclerosis
patients with active digital ulcers.
The average number of new digital ulcers over 16 weeks
was low, ranging from 0.85 to 1.46 ulcers across the treat-
ment groups in both studies. Approximately 60% of patients
did not develop new digital ulcers. Even among patients with
more than 3 active digital ulcers at baseline, the average num-
ber of new digital ulcers over 16 weeks ranged from 1.16 to 2.66
in the 3 treatment groups. In RAPIDS-1,11 patients treated with
placebo with 1 to 3 active digital ulcers at baseline developed,
a mean (SD) of 2.2 (2.0) new digital ulcers over 16 weeks, and
those with more than 3 active digital ulcers at baseline devel-
oped 5.1 (3.9) new ulcers. Overall, 42% of the patients in
RAPIDS-1 had more than 3 new digital ulcers over 16 weeks.11
Results were similar in RAPIDS-2.12 DUAL-1 and DUAL-2 were
designed with the expectation that patients receiving pla-
cebo would develop more digital ulcers.
Patients enrolled in DUAL-1 and DUAL-2 had similar de-
mographics and disease characteristics as patients enrolled in
prior systemic sclerosis digital ulcer trials. The low number of
new digital ulcers observed suggests that the epidemiology of
digital ulcers in systemic sclerosis may be changing and re-
flect earlier diagnosis, better care, and greater availability of
treatments. A similarly low incidence of new digital ulcers in
patients with systemic sclerosis was also observed in a recent
study.26 Standard management of digital ulcers has im-
proved in recent years with the widespread use of bosentan,
PDE-5 inhibitors, and prostacyclin and its analogs.27,28 It is pos-
sible that patients with more severe active ulcers were treated
with these medications and not recruited into the DUAL trials
or that the studies enrolled a population with refractory digi-
tal ulcers that did not respond well to standard treatments. En-
rolled patients may have exhausted other treatment options.
The overexpression of ET-1 and ET receptors in skin, the
epidermis, and blood vessels in systemic sclerosis is well
documented.10,29-31 However, the specific role of ET-1 in the
pathogenesis of digital vasculopathy and the development of
digital ulcers in systemic sclerosis is incompletely under-
stood. Although bosentan and macitentan both block the ETA
and ETB receptors, a reduction in the formation of new digital
ulcers has only been observed with bosentan.11,12 Macitentan
is a more potent ERA than bosentan on ET receptors in vitro
and on biomarkers (eg, plasma ET-1) and other measures
(eg, blood pressure and cardiac remodeling) in in vivo mod-
els of pulmonary hypertension.32 It is unclear why this rela-
tive higher potency of macitentan did not result in an effect
on digital ulcers. Further research is necessary to delineate
mechanisms of vascular involvement in systemic sclerosis as
it relates to digital ulcers. The etiology of digital ulceration in
systemic sclerosis is multifactorial, involving ischemic, in-
flammatory, and mechanical mechanisms, all of which influ-
ence clinical outcomes of digital ulcers, including repetitive
microtrauma, thinning, dry skin, and underlying calcinosis.
Limitations of the DUAL-1 and DUAL-2 studies include the
lack of a clear classification system of digital ulcers that con-
siders digital ulcer morphology and the different ulcer fea-
tures, including presence of underlying calcinosis, size, bed-
ding, perilesional skin, and borders, which potentially affect
digital ulcer assessment and counts.6,7 The DUAL studies in-
volved 73 centers in 20 countries. Although efforts were made
to standardize the definition and the reporting of new active
digital ulcers, some variability across the study sites in mea-
suring new digital ulcers was likely, and the absence of inter-
rater reliability data to quantify this is a limitation. In addi-
tion, 23.5% of participants in DUAL-1 and 24.9% of those in
DUAL-2 were missing primary outcome data at 16-week follow-
up. However, the primary end point considers the cumula-
tive number of new digital ulcers up to week 16, and the con-
sistency of sensitivity analyses suggests that missing data did
not significantly affect statistical inference. Differences in phy-
sician attitudes and standard practices,17 and the lower than
expected number of new digital ulcers after 16 weeks may have
ultimately influenced the ability to demonstrate any treat-
ment effect in the DUAL trials.
Conclusions
Among patients with systemic sclerosis and active ischemic
digital ulcers, treatment with macitentan did not reduce the
number of new digital ulcers over 16 weeks. These results do
not support the use of macitentan for the treatment of digital
ulcers in this patient population.
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